FDA Grants Priority Review for Prostrate Cancer Treatment
The FDA granted a Priority Review designation to Pfizer and partner Astellas Pharma for expanded use of Xtandi in prostrate cancer treatment.
Source: BioSpace
The FDA granted a Priority Review designation to Pfizer and partner Astellas Pharma for expanded use of Xtandi in prostrate cancer treatment.
Source: BioSpace